Answers are grounded in this paper and cite their sources.
Chronic kidney disease affects >13% of adults worldwide, yet no approved antifibrotic therapy is available. Recent advances in single‑cell and spatial transcriptomics have transformed the understanding of renal fibrosis. These technologies have unmasked unexpected heterogeneity among myofibroblasts and macrophages, identified scar‑associated macrophage subsets and resolved the long‑standing debate over myofibroblast origins by confirming resident fibroblasts as the principal source. Spatial transcriptomics has further defined functional communities and pathologically distinct niches, including maladaptive repair niches centred on SOX9+ epithelial cells, profibrotic microenvironments enriched in tenascin‑C and immune‑activation niches where macrophages and fibroblasts co‑localize. Intercellular crosstalk networks involving TGF‑β, NOTCH and paracrine signals from injured tubules have been systematically mapped. These insights are now being translated into targeted strategies, such as surface marker‑directed agents against CD248 and fibroblast activation protein, epigenetic modulators including HDAC6 inhibitors and advanced 3D bioprinted human models. The present review synthesized these single‑cell and spatial discoveries to provide a conceptual framework for developing precision antifibrotic therapies for progressive kidney disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: